Compare Keysight Technologies Inc (KEYS) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Medtronic PLC — how do they compare? Keysight Technologies Inc trades at $382.61 (market cap $63.79B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays a 3.28% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Medtronic PLC for 63 Days on average.
| KEYS | MDT | |
|---|---|---|
Market Cap | $63.79B | $112.24B |
Volume | 1,435,384 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $387.90 | $105.35 |
52-Week Low | $159.49 | $73.75 |
Typical Hold Time | 56 Days | 63 Days |
Enterprise Value | $63.93B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.61, up 0.29% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with accelerating earnings, beating estimates for three consecutive quarters, and impressive profitability metrics including 19.14% net income margin and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, positioning the company for continued growth.
KEYS presents a compelling investment case with strong analyst consensus (81% buy ratings) and a $416.63 price target offering 8.9% upside. However, elevated valuation ratios (P/E 50.7, P/S 9.85) and supply chain constraints present near-term risks. The company's leadership in AI testing and 6G technology provides long-term growth catalysts despite current premium pricing.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
